Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in <i>EGFR</i> -Mutant Non–Small Cell Lung Cancer Cells

Kei Namba, Kazuhiko Shien, Yuta Takahashi, +10

Molecular Cancer Research

Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer

Tatsuaki Takeda, Hiromasa Yamamoto, Hirotaka Kanzaki, +17

PLoS ONE

Acquired resistance mechanisms to afatinib in <i><scp>HER</scp>2</i>‐amplified gastric cancer cells

Takahiro Yoshioka, Kazuhiko Shien, Tatsuaki Takeda, +11

Cancer Science

Therapeutic strategies for afatinib‐resistant lung cancer harboring <i><scp>HER</scp>2</i> alterations

Hidejiro Torigoe, Kazuhiko Shien, Tatsuaki Takeda, +11

Cancer Science

YES1 activation induces acquired resistance to neratinib in <i>HER2</i>‐amplified breast and lung cancers

Tatsuaki Takeda, Hiromasa Yamamoto, Ken Suzawa, +12

Cancer Science

Drug repositioning of tranilast to sensitize a cancer therapy by targeting cancer‐associated fibroblast

Kosuke Ochi, Ken Suzawa, Yin Min Thu, +13

Cancer Science

Overcoming epithelial-mesenchymal transition-mediated drug resistance with monensin-based combined therapy in non-small cell lung cancer

Kosuke Ochi, Ken Suzawa, Shuta Tomida, +15

Biochemical and Biophysical Research Communications

MedicinePharmacologyBronchial NeoplasmAnti-cancer AgentCancer Treatment +5

YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development

M. Fujihara, Tadahiko Shien, Kazuhiko Shien, +17

International Journal of Molecular Sciences

Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer

Eisuke Kurihara, Kazuhiko Shien, Hidejiro Torigoe, +13

Anticancer Research

Differential Combined Effect of COX Inhibitors on Cell Survival Suppressed by Sorafenib in the HepG2 Cell Line

Kenta Yagi, Yoichi Kawasaki, Hiroko Nakamura, +6

Biological and Pharmaceutical Bulletin

Cell DeathPathologyPharmacotherapyHepg2 Cell LineHcc Therapy +14